Thermo Fisher Scientific Inc. $TMO Shares Sold by Belpointe Asset Management LLC

Key Points

• Belpointe Asset Management LLC reduced its holdings in Thermo Fisher Scientific by 9.5%, selling 551 shares, which left them with a total of 5,276 shares valued at approximately $2.14 million.
• Several investment firms, including Valley National Advisers Inc. and DAVENPORT & Co LLC, have increased their stakes in Thermo Fisher Scientific during the same period, indicating ongoing institutional interest in the stock.
• Analysts have set a new average price target of $585.37 for Thermo Fisher Scientific, with multiple firms rating it as an "outperform" or "buy."

Belpointe Asset Management LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 5,276 shares of the medical research company's stock after selling 551 shares during the period. Belpointe Asset Management LLC's holdings in Thermo Fisher Scientific were worth $2,139,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Valley National Advisers Inc. increased its holdings in Thermo Fisher Scientific by 1.5% during the 2nd quarter. Valley National Advisers Inc. now owns 3,282 shares of the medical research company's stock valued at $1,329,000 after acquiring an additional 50 shares in the last quarter. Duncan Williams Asset Management LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $206,000. DAVENPORT & Co LLC lifted its stake in Thermo Fisher Scientific by 8.1% in the 2nd quarter. DAVENPORT & Co LLC now owns 5,048 shares of the medical research company's stock valued at $2,047,000 after buying an additional 380 shares in the last quarter. Marks Group Wealth Management Inc grew its holdings in Thermo Fisher Scientific by 3.2% during the 2nd quarter. Marks Group Wealth Management Inc now owns 9,692 shares of the medical research company's stock valued at $3,930,000 after buying an additional 305 shares during the last quarter. Finally, Grimes & Company Inc. raised its holdings in shares of Thermo Fisher Scientific by 0.9% in the second quarter. Grimes & Company Inc. now owns 16,143 shares of the medical research company's stock worth $6,545,000 after acquiring an additional 144 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Raymond James Financial reiterated an "outperform" rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Finally, William Blair started coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $585.37.

Thermo Fisher Scientific Trading Up 0.2%

Shares of TMO opened at $544.44 on Tuesday. The stock's fifty day simple moving average is $483.77 and its 200 day simple moving average is $446.95. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $205.59 billion, a P/E ratio of 31.49, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the business posted $5.37 EPS. The company's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.